Prostate Cancer Screening Guidance for Men ≥ 75 Years Old

1. Screening Cessation Criteria

PSA testing should be stopped in men older than 75 years unless they are exceptionally healthy with an estimated life expectancy > 10–15 years and minimal comorbidities. 1
Continuing screening in men ≥ 75 years markedly raises overdiagnosis without improving life expectancy, even when PSA values are elevated. 1
The NCCN advises that PSA testing after age 70 years be individualized and performed only in very healthy men with little or no comorbidity, because most detected cancers would not affect survival. 1

Asymptomatic men whose life expectancy is < 10 years should not be offered prostate‑cancer screening because the potential harms outweigh uncertain benefits. 2
At age 87, the average remaining life expectancy is roughly 5–6 years, well below the 10‑year threshold needed to realize a screening benefit. 2
The U.S. Preventive Services Task Force recommends against PSA screening in men older than 75 years, recognizing that the average male at this age has ≤ 10 years of expected life. 3
Only men with excellent health, no significant comorbidities, and a family history suggesting longevity should be considered for screening beyond 75 years. 3

Screening in older men leads to a high rate of overdiagnosis—detecting cancers that will never cause morbidity or mortality during the patient’s remaining lifespan. 2
Associated harms include false‑positive results, unnecessary biopsies (with pain, bleeding, infection), anxiety, and overtreatment that can cause urinary incontinence, erectile dysfunction, and bowel problems. [4][2]

Life expectancy > 10–15 years based on robust functional status and absence of major comorbidities. [1][2]
Symptomatic lower urinary‑tract symptoms that warrant investigation for causes other than cancer (e.g., benign prostatic hyperplasia). 5
Patient’s informed preference for continued screening after detailed counseling about the high likelihood of detecting clinically insignificant disease and the substantial treatment‑related harms. [4][2]

Do not perform a prostate biopsy solely because of an elevated PSA in men ≥ 75 years without first assessing life expectancy. [1][2]
Do not screen men with significant comorbidities (e.g., cardiovascular disease, diabetes, chronic lung disease, dementia) or functional limitations, as they are unlikely to benefit. [3][2]
Do not assume that cancer detection automatically confers a clinical benefit; most cancers identified in elderly men are indolent and will not affect survival. 2
Do not overlook patient values; many older men prefer to avoid the anxiety and potential harms of further testing even when they are otherwise healthy. [4][2]

Discontinue PSA testing and do not repeat it in the future. [1][2]
Perform a digital rectal examination only if the patient presents with urinary symptoms requiring evaluation; if the exam is normal, no further prostate work‑up is needed. 5
Counsel the patient that the current PSA level falls within the expected range for his age and that additional screening is more likely to cause harm than benefit. [4][2]
Monitor for concerning symptoms such as bone pain, unexplained weight loss, or severe urinary obstruction that could indicate advanced disease requiring palliative care (not routine screening). 5
Reassess the need for any further prostate evaluation only if a palpable prostate nodule is discovered on examination or if symptoms suggest metastatic disease. (No citation needed because the supporting source is Praxis, which is excluded.)